Serve Robotics Inc.

Symbotic Inc.

NIO Inc.

Motley Fool analyst Leo Sun has <a href="https://www.fool.com/investing/2025/10/28/growth-stocks-that-could-be-10-baggers-in-10-years/">highlighted</a>&nbsp;three undervalued stocks that, in his view, could deliver tenfold returns over the next decade. One of them is small-cap company Serve Robotics, a developer of autonomous delivery robots. The other two are warehouse-automation firm Symbotic and Chinese EV maker Nio.

Motley Fool names three growth stocks with 10x upside over a decade

Avidity Biosciences, Inc.

Novartis AG

Shares of Avidity Biosciences, a small developer of therapies for rare diseases including Duchenne muscular dystrophy, jumped more than 40% yesterday, October 27, to an all-time high. Investors reacted to news that Switzerland’s Novartis <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html">plans</a>&nbsp;to acquire the company at a premium to the market. The move sends a signal to investors in small-cap biotech: pharma majors increasingly prefer to buy externally developed assets rather than build them in-house. More transactions can be expected in the coming months, Noble Capital Markets <a href="https://www.channelchek.com/news-channel/novartis-12-billion-avidity-acquisition-strengthens-its-rare-disease-pipeline-amid-pharma-tariff-uncertainty">said</a>&nbsp;in a post.

Novartis $12 bln deal for Avidity sparks mid-cap biotech rally


Unitil Corporation

Global Water Resources, Inc.

Sky Harbour Group Corporation

Millrose Properties, Inc.

Industrial Logistics Properties Trust

The U.S. Federal Reserve will publish its interest rate decision on Wednesday, October 29. The market <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">expects a</a> decrease by 0.25 p.p. - To 3.75-4%. Its previous revision in September 2025 led to a revival of the stock market, and the "clear winner" of this analysts <a href="https://oninvest.com/article/avnyj-pobeditel-indeks-russell-2000-ustanovil-pervyj-rekord-za-cetyre-goda">called</a> small-capitalization companies, which are included in the Russell 2000 index. The day after the Fed's decision, Sept. 18, the index set its first record in four years, jumping 2%. Over the past six months, the Russell 2000 <a href="https://finance.yahoo.com/quote/%5ERUT/">has added</a> 28.4%, outperforming the S&amp;P 500 index, the benchmark for large-cap companies. It is <a href="https://finance.yahoo.com/quote/%5ESPX/">up</a> 23.8% over the same period.

The market is waiting for a Fed rate cut. Five small-cap companies that can benefit from it

Beyond Meat, Inc.

Alector, Inc.

Freedom Broker has pointed out the two small-cap stocks with the most pronounced moves last week (October 20-24). The outperformer was plant-based meat producer Beyond Meat, while the underperformer was biopharma company Alector, a developer of therapies for dementia.

Freedom Broker names biggest small cap outperformer and underperformer from last week

Twin Hospitality Group Inc.

The fair value of shares of small-cap restaurant operator Twin Hospitality Group is $10 apiece, or 154% above <a href="https://finance.yahoo.com/quote/TWNP/">current quotes</a>, Noble Capital Markets estimates in a <a href="https://dashboard.channelchek.com/wp-content/uploads/pdf/TWNP_20251021_27732.pdf">coverage initiation report</a> on the company. The analysts say the company has considerable scope to expand, both by adding new restaurants and by tightening operations.

Noble initiates on small-cap restaurant stock Twin Hospitality with 150% upside

Investors who were betting against plant-based meat producer Beyond Meat <a href="https://www.businessinsider.com/beyond-meat-stock-short-sellers-meme-rally-retail-traders-bynd-2025-10?IR=T">lost</a>&nbsp;about $120 million in less than a week. The four-day <a href="https://en.oninvest.com/article/symbol-of-rebellion-beyond-meat-stock-rockets-466-in-two-days">rally</a>&nbsp;in the small cap sent the shares up nearly 1,400%, with Beyond Meat being called a meme stock.

Short sellers lose $120 million in a week as Beyond Meat rallies nearly 1,400%

Vicor Corporation

Quotes of Vicor Corporation, which makes&nbsp;modular power components and complete power systems, jumped 30% yesterday, October 22, after the company <a href="https://vicorcorporation.gcs-web.com/news-releases/news-release-details/vicor-corporation-reports-results-third-quarter-ended-15">reported</a>&nbsp;quarterly results that <a href="https://finance.yahoo.com/news/why-vicor-stock-skyrocketed-today-211039597.html">beat</a>&nbsp;Wall Street expectations. The earnings&nbsp;<a href="https://www.barrons.com/articles/vicor-stock-ai-power-demand-290abf65?mod=RTA">prompted</a>&nbsp;several analysts to raise their recommendations on the stock.

Power-systems maker Vicor soars on strong, AI-boosted earnings and analyst upgrades

BioAge Labs

Citigroup has upgraded to "buy" shares of small-cap obesity drug developer BioAge Labs, calling the company’s lead molecule promising, with the first-in-human study recently <a href="https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-first-participant-dosed-phase-1-clinical">announced</a>. The upgrade <a href="https://finance.yahoo.com/quote/BIOA/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAANJzO7qhtq4ftfonGEodVUta3W7CcmJ8wkHgYAForTOSW-XBS4xlKF7KLyQk0L35CoYcX_jqygts2GD4qGMiFBIdNwS4SdNJF98C33sKbOp9lSNggPnmigup5BLKbWDPzB_A28f6kwvxv2u7wovLH2Nc3V4Qa7V3KMWqsBlp24tN">sent</a>&nbsp;the stock up more than 14%. Citigroup believes it could rise a further 70%.

Citigroup upgrades rating, TP on obesity drugmaker BioAge amid upcoming clinical data

Minerva Neurosciences, Inc.

Quotes of Minerva Neurosciences, a micro-cap developer of a drug against negative symptoms in patients with schizophrenia, <a href="https://finance.yahoo.com/quote/NERV/">soared</a>&nbsp;140% in one day. The company, which is worth just $44.8 million on the Nasdaq, <a href="https://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-financing-200-million-advance">said</a>&nbsp;it had raised up to $200 million to complete trials of its drug and will, if they prove successful, file for approval and prepare for a commercial launch.

Maria Dranishnikova

Writes about:

Articles: 620